Overview

Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

The investigators want to see if healthy people who are given 2 doses of a medication called anakinra, which is used to treat moderate to severe rheumatoid arthritis, (RA) and then exposed to a form of air pollution, called Endotoxin, have less inflammation with the medication. Endotoxin is believed to be one of the causes of asthma attacks.

Phase:

Phase 1

Details

Lead Sponsor:

Michelle Hernandez, MD

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Interleukin 1 Receptor Antagonist Protein